Value proposition

Guiding clinicians towards personalized treatment and enhancing quality of life for patients

Using molecular structures to choose the best therapy. Currently focusing on mutations in EGFR and other lung cancer drivers. Working closely with the Molecular Tumor Board at the UMCG #umcg and patient organizations across Europe.